Contezolid tablet (MRX-I tablets) is successfully renewed for inclusion in the National Reimbursement Drug List (NRDL) at the original price in China.

Contezolid tablet (MRX-I tablet) is added to the most recent National Reimbursement Drug List (NRDL) in China.

China National Medical Products Administration (NMPA) approves Contezolid tablet (MRX-I tablet), for treatment of Complicated Skin and Soft Structure Infection

NDA of MRX-I tablets accepted and priority review granted by the National Medical Products Administration (NMPA)
MRX-8 IND approved in the US
Series D and E Financing

MRX-I Phase 3 clinical trial completed and New Drug Application (NDA) submitted in China
MRX-4 Phase 2 clinical trial in the US

Qualified Infectious Disease Product (QIDP) and Fast Track granted for MRX-I and MRX-4 in the US
MRX-4 IND approved in China

MRX-4 Phase 1 clinical trial in the US

MRX-I Phase 2 clinical trial completed in the US
Series C financing

MRX-I Phase 2 clinical trial completed in China
Patents for MRX-4 and MRX-8 filed

MRX-I Phase 1 clinical trial in Australia

Series B financing
MRX-I supplementary application approved in China

MRX-I supplementary application submitted in China

MRX-I Phase 1 clinical trial in China

MRX-I IND approved in China

MRX-I investigation new drug (IND) application submitted in China

First drug candidate MRX-I discovered, patent filed

MicuRx founded in Shanghai and California
Series A financing